When was Profluent Bio founded?

Profluent Bio was founded in 2022 and raised its 1st funding round 1 year after it was founded.

Where is Profluent Bio located?

Profluent Bio is headquartered in Berkeley, United States.

Who is the current CEO of Profluent Bio?

Ali Madani of Profluent Bio. They have also founded 1 company.

How many employees does Profluent Bio have?

As of Mar 31, 2026, the latest employee count at Profluent Bio is 57.

Is Profluent Bio a funded company?

Profluent Bio is a funded company, having raised a total of $150M across 3 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Jan 26, 2023.

When was the latest funding round of Profluent Bio?

Profluent Bio's latest funding was a $***** Series B round on Nov 19, 2025, with participation from 5 investors.

Where does Profluent Bio rank among its competitors?

Profluent Bio ranks 3rd amongst 65 active competitors, of which 37 are funded. It stands 6th in terms of total funding among its competitors. The most recent competitor to raise funding was Converge, which secured $25M in Jan, 2026.

Who are the top competitors of Profluent Bio?

Profluent Bio's top competitors include Nimbus Therapeutics, Vividion Therapeutics and Generate Biomedicines. Among them, Converge secured the most recent funding round in January, 2026.

Profluent Bio - 2026 Company Profile, Team, Funding & Competitors

Profluent Bio is a series B company based in Berkeley (United States), founded in 2022 by Ali Madani and Alexander Meeske. It operates as a Provider of an artificial intelligence-based protein design platform. Profluent Bio has raised $150M in funding from investors like Insight Partners, Spark Capital and Bezos Expeditions. The company has 65 active competitors, including 37 funded and 4 that have exited. Its top competitors include companies like Nimbus Therapeutics, Vividion Therapeutics and Generate Biomedicines.

Company Details

Provider of an artificial intelligence-based protein design platform. It uses deep generative models to design novel, functional proteins that can be used in drug discovery.

Website: www.profluent.bio/
Email ID: *****@profluent.bio

Key Metrics

Founded Year

2022

Location

Berkeley, United States

Stage

Series B

Total Funding

$150M in 3 rounds

Latest Funding Round

Series B, Nov 19, 2025, $*****

Investors

Insight Partners & 7 more

Ranked

3^rd among 65 active competitors

Employee Count

57 as on Mar 31, 2026

Similar Companies

Innovaccer & 2363 more

View Profluent Bio's full profile

Profluent Bio is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Profluent Bio Inc. CIN: 88-3009864 , United States, Active		-	-	-

Profluent Bio has raised a total funding of $150M over 3 rounds. Its first funding round was on Jan 26, 2023. Its latest funding round was a Series B round on Nov 19, 2025 for $*****. 5 investors participated in its latest round. Profluent Bio has 8 institutional investors.

Here is the list of recent funding rounds of Profluent Bio:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Nov 19, 2025	9634423	Series B	1430226	2778813	8820572	9912897
Mar 21, 2024	1288937	Series A	9355458	2789978	8233367	Insight Partners & 1 more
Jan 26, 2023	7429728	Seed	7898491	9123957	Insight Partners	Air Street Capital & 3 more

Access funding benchmarks and valuations. Sign up today!

View details of Profluent Bio's funding rounds and investors

The founders of Profluent Bio are Ali Madani and Alexander Meeske. Ali Madani is the CEO of Profluent Bio.

Here are the details of Profluent Bio's key team members:

Ali Madani: Co-Founder & CEO of Profluent Bio.
Contact Info: 1 email address
Alexander Meeske: Co-Founder of Profluent Bio.
Contact Info: 1 email address

View details of Profluent Bio's Founder profiles and Board Members

Profluent Bio's employee count trend

Profluent Bio has 57 employees as of Mar 26. Here is Profluent Bio's employee count trend over the years:

Uncover Profluent Bio's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Profluent Bio include Nimbus Therapeutics, Vividion Therapeutics and Generate Biomedicines. Here is the list of Top 10 competitors of Profluent Bio, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Nimbus Therapeutics 2009, Cambridge (United States), Series F	Developer of targeted therapeutics for cancer, metabolic and inflammatory diseases	$637M	BVF Partners, Atlas Venture & 20 others	68/100
2nd	Vividion Therapeutics 2016, Oceanside (United States), Acquired	Pioneering chemoproteomics and covalent chemistry for precision therapeutics targeting undruggable disease drivers	$271M	Boxer Capital, Logos & 20 others	65/100
3rd	Profluent Bio 2022, Berkeley (United States), Series B	Provider of an artificial intelligence-based protein design platform	$150M	Bezos Expeditions, Spark Capital & 6 others	64/100
4th	Generate Biomedicines 2018, Somerville (United States), Series C	Developer of a platform for generating novel protein-based therapeutic modalities	$693M	March Capital, Amgen & 14 others	63/100
5th	Seismic 2019, Watertown (United States), Series B	AI-assisted platform for drug discovery and development	$247M	Bessemer Venture Partners, Lightspeed Venture Partners ... & 12 others	63/100
6th	Eikon 2019, Hayward (United States), Public	Protein tracking and measuring tool for drug discovery	$1.16B	The Column Group, ADIA & 22 others	62/100
7th	AI Proteins 2021, Boston (United States), Series A	Developer of de novo designed miniproteins for therapeutic applications	$59.7M	Mission BioCapital, Sante & 3 others	57/100
8th	Nomic 2017, Montreal (Canada), Series B	Provider of next-generation proteomics platform for drug discovery and protein analysis	$63M	Lux Capital, Amplitude & 13 others	56/100
9th	Orbit Discovery 2015, Oxford (United Kingdom), Series A	Developer of a drug discovery platforms by peptide display engine	$15.7M	Oxford Science Enterprises, Oxford University Innovation ... & 11 others	54/100
10th	Converge 2024, Wilmington (United States), Series A	Developer of GenAI computational tools for drug discovery and manufacturing	$30.5M	TLV Partners, Bessemer Venture Partners & 2 others	53/100